Whitehawk Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
07/08/2025 18:22
Whitehawk Therapeutics Inc WHWK.OQ reported a quarterly adjusted loss of 76 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -54 cents. The mean expectation of three analysts for the quarter was for earnings of 49 cents per share. Wall Street expected results to range from -45 cents to $2.10 per share. Reported revenue was zero; analysts expected $33.33 million. Whitehawk Therapeutics Inc's reported EPS for the quarter was a loss of 76 cents. The company reported a quarterly loss of $52.62 million. Whitehawk Therapeutics Inc shares had fallen by 3.7% this quarter and lost 42.9% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 9.2% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy." Wall Street's median 12-month price target for Whitehawk Therapeutics Inc is $2.00, about 10% above its last closing price of $1.80 This summary was machine generated from LSEG data August 7 at 05:21 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | 0.49 | -0.76 | Missed |
| Mar. 31 2025 | -0.46 | -0.37 | Beat |
| Dec. 31 2024 | -0.22 | -0.67 | Missed |
| Sep. 30 2024 | -0.46 | -0.46 | Met |